| Autor: |
Ulgen BO; Center for Heart and Vessel Preclinical Studies, St. John Hospital and Medical Center, Wayne State University School of Medicine, USA., Field MG, Qureshi W, Knight RA, Stephanou A, Latchman DS, Vasquez D, Barry SP, Saravolatz L 2nd, Scarabelli GM, Faggian G, Mazzucco A, Saravolatz L, Chen-Scarabelli C, Scarabelli TM |
| Jazyk: |
angličtina |
| Zdroj: |
Recent patents on cardiovascular drug discovery [Recent Pat Cardiovasc Drug Discov] 2011 May; Vol. 6 (2), pp. 123-32. |
| DOI: |
10.2174/157489011795933783 |
| Abstrakt: |
Minocycline is a semi-synthetic tetracycline that inhibits bacterial protein synthesis and hence is used for the treatment of many infectious diseases. Over the years, many other interesting properties of minocycline have been identified and been used to make patents which include anti-inflammatory, anti-apoptotic, matrix metalloproteinase inhibitor and free oxygen radical scavenger activity. Ischemia-reperfusion injury is a concern for almost every clinical specialty and minocycline seems to be an attractive cytoprotective agent that can ameliorate the damage due to these properties. Ischemia-reperfusion injury is a complex process and involves various pathways that lead to cell death. This review focuses on the body of evidence describing various proposed mechanisms of action of minocycline and its current experimental use in various animal models of ischemia-reperfusion injury. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
